Upstream Bio stock

Upstream Bio Stock

HealthTech

Looking to sell Upstream Bio stock or options?

Founded: 2021Funding to Date: $400Mhttps://www.upstreambio.com

Upstream Bio Inc, a clinical-stage biotechnology company, is focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders. Its lead product, verekitug, is an antagonist in clinical development targeting the receptor for Thymic Stromal Lymphopoietin (TSLP). This cytokine is a validated driver of inflammatory responses and impacts various immune-mediated diseases by acting upstream of multiple signaling pathways.

Investors Include:

Maruho, Access Biotechnology, Bain Capital Life Sciences, Samsara BioCapital, Wellington Management, HBM Partners, TCG Crossover Management, Altshuler Shaham Investment House, OrbiMed, Enavate Sciences, HBM Healthcare Investments, Venrock, Omega Funds, Decheng Capital.

Collective explained in 2 minutes

Learn how Collective's solutions enable you to manage your risk and maximize your wealth

Learn more